In the next phase of the trial, about 10,000 more individuals will be given the vaccine in May and June, Pollard stated.
The head of the Oxford Vaccine Group, Andrew Pollard, stated on Friday that clinical trials of its coronavirus vaccine prospect were advancing well and that the program would inoculate about 10,000 more people.
” The scientific studies are advancing very well and we are now starting research studies to assess how well the vaccine induces immune reactions in older adults,” Pollard said in a press release.
The group said more than 1,000 individuals in the UK– omitting children and individuals over 55– had been offered the speculative vaccine.
YouTube/University of Oxford.
The group said that results from that trial might be readily available in 2 to six months. Its progress might be prevented if the UK’s coronavirus outbreak slows, since it indicates fewer people will be exposed naturally to the infection, it said.
The group stated that to reduce this, it was focusing on hiring volunteers “who have a greater possibility of being exposed,” like frontline health care workers.
The Oxford Vaccine Group is one of a few elite labs and centers in the race to find a coronavirus vaccine.
On Monday, the United States firm Moderna laid out favorable data from a phase-one trial of its vaccine candidate.
The drug giant Pfizer partnered with BioNTech to start human trials of its speculative vaccine on May 5.
Sean Elias/Handout through REUTERS.
In overall, about 12 coronavirus vaccines in development worldwide are in human trials or about to begin them, The Associated Press reported on Friday.
Sarah Gilbert, a professor of vaccinology working on the Oxford vaccine, said on April 11 that the earliest it might be ready was September– but that such a date was extremely positive.
Whether the vaccine will be approved, it is already in high need.
On Thursday, the US government consented to pay up to $1.2 billion to protect 300 million doses of the Oxford group’s vaccine.
Last month, the Serum Institute of India, the world’s biggest vaccine-maker by number of doses, said it would make as numerous as 40 million dosages.
” The choice– at our own threat and expense– has actually been entirely required to get a jump-start on production,” stated Adar Poonawalla, the institute’s CEO.
In spite of the progress, there are concerns that even if a vaccine is authorized, an international rollout will be hampered by a lack of the glass vials and lids required to disperse the doses.